Physician profile
Okosun E Edoro
NPI 1063611481
$938.88
in general payments reported to CMS, 2019-2025
13 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $11.56 · 2021: $29.99 · 2022: $309 · 2023: $23.81 · 2024: $30.47 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.25 | 2021-2025 | |
| Novo Nordisk INC | $175.06 | 2022-2025 | Rybelsus, Ozempic |
| Galderma Laboratories, L.P. | $164.61 | 2019-2020 | |
| Lilly USA, LLC | $80.40 | 2022-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $41.28 | 2022-2023 | Trintellix |
| Xeris Pharmaceuticals, INC. | $40.91 | 2022-2025 | Keveyis |
| Boston Scientific Corporation | $27.81 | 2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $24.37 | 2025 | Trelegy Ellipta |
| Pfizer INC. | $22.26 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.62 | 2022 | |
| Verona Pharma, INC. | $17.35 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $15.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Okosun Edoro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.